Third Arc Bio, led by three former Johnson & Johnson executives, is advancing a portfolio of multifunctional antibodies for cancer and inflammatory and immune-mediated diseases.
Tag Archive for: Johnson & Johnson
Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.
Emergent BioSolutions said Johnson & Johnson has agreed to pay $50 million to settle claims related to a terminated manufacturing deal for the latter’s COVID-19 vaccine.
The companies leased interim results from the Phase III CARTITUDE-4 study, touting significant survival improvement in multiple myeloma patients after treatment with their CAR-T therapy Carvykti (ciltacabtagene autoleucel).
The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.
Johnson & Johnson is facing a new proposed class action seeking damages and medical monitoring on behalf of women who have been diagnosed with cancer, or might develop it in the future, allegedly as a result of using the company’s baby powder and other talc products.
After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.
Johnson & Johnson’s FcRn inhibitor nipocalimab in a mid-stage study significantly improved disease activity across various organ systems in patients with the chronic autoimmune Sjögren’s disease.
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.
Today the company said its experimental drug helped reduce symptoms of major depressive disorder (MDD) and insomnia in a late-stage trial when given along with commonly used antipsychotic treatments.